Back to Search
Start Over
A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2− Metastatic Breast Cancer
- Source :
- Clinical Breast Cancer. 20:e232-e243
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- PIK3CA mutations may have prognostic value for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, representing an important potential target for systemic therapy. Prognostic and predictive values associated with PIK3CA mutations are not well understood. A comprehensive search of PubMed/MEDLINE, EMBASE, Cochrane Central, and conference abstracts was performed for English-language articles published January 1993 through April 2019. Articles were categorized by treatment arms based on experimental and treatment drug classes. Information on progression-free survival (PFS), hazard ratios, overall survival, response rate, and clinical benefit rate was obtained. A total of 17 studies were included. Among those evaluating non-PI3Ki based therapies, 91% showed numerically shorter median PFS, ranging from 1.5 to 19.2 months and 1.8 to 29.6 months for the mutant versus non-mutant subgroups, respectively. Where reported (n = 13 studies), PFS was shorter between those arms offering endocrine monotherapy (range, 1.6-14.7 months) compared with a corresponding targeted therapy + endocrine monotherapy (range, 3.9-29.6 months). Of 5 PI3Ki-based arms comparing PFS, higher median PFS in PIK3CA mutant versus non-mutant cases was demonstrated. PFS was shorter for patients with PIK3CA mutant (range, 1.6-19.2 months) compared with PIK3CA wild-type (range, 1.8-29.6 months) in 10 (71%) of 14 treatment arms reporting PFS. Studies (n = 4) not reporting PFS reported response rate, but there were no clear directional trends. The presence of PIK3CA mutations may be associated with worse clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Clinical outcomes such as PFS may be improved using a combination of PI3Ki-based therapies and endocrine therapies among this population. However, more research is warranted to fully elucidate this association.
- Subjects :
- 0301 basic medicine
Response rate (survey)
Oncology
Cancer Research
medicine.medical_specialty
education.field_of_study
business.industry
Hazard ratio
Population
medicine.disease
Metastatic breast cancer
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Breast cancer
030220 oncology & carcinogenesis
Internal medicine
medicine
Biomarker (medicine)
Endocrine system
business
education
neoplasms
Hormone
Subjects
Details
- ISSN :
- 15268209
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Clinical Breast Cancer
- Accession number :
- edsair.doi...........45bb916422ae7569c7396f894f808ce5
- Full Text :
- https://doi.org/10.1016/j.clbc.2019.08.011